SAB Biotherapeutics (SABS) Assets (2020 - 2026)

SAB Biotherapeutics' Assets history runs 7 years deep, the most recent figure standing at $248.5 million for Q1 2026.

• Quarterly Assets rose 551.81% year-over-year to $248.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $248.5 million (up 551.81% YoY) and the FY2025 annual result came in at $172.8 million, up 291.01% from the prior year.
• Assets was $248.5 million for Q1 2026 at SAB Biotherapeutics, up from $172.8 million in the prior quarter.
• Across five years, Assets topped out at $248.5 million in Q1 2026 and bottomed at $28.3 million in Q3 2023.
• A 5-year average of $78.0 million and a median of $53.8 million in 2024 frame the typical range for Assets.
• Annual changes were most pronounced in 2022 — Assets tumbled 55.09% — and 2026, when it surged 551.81%.
• SAB Biotherapeutics' Assets stood at $50.9 million in 2022, then jumped by 64.9% to $83.9 million in 2023, then sank by 47.35% to $44.2 million in 2024, then jumped by 291.01% to $172.8 million in 2025, then jumped by 43.78% to $248.5 million in 2026.
• Business Quant data shows SABS's Assets at $248.5 million in Q1 2026, $172.8 million in Q4 2025, and $183.4 million in Q3 2025.